Hasan Yazici
Research Subjects
Hasan Yazici has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Yusuf Yazici
NYU Grossman School of Medicine, New York, New York, USA
11 shared publications- Yusuf Yazici
New York University School of Medicine, New York, New York, USA
10 shared publications - Emire Seyahi
Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye
3 shared publications - Eldad Ben-Chetrit
Rheumatology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
2 shared publications - Emmanuel Lesaffre
Erasmus MC
2 shared publications Gulen Hatemi
2 shared publications
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
Uncertainty in medicine and vasculitis
Purpose of review: We propose that clinicians/researchers attempt to address the continuing uncertainty of the root causes of the conditions we try to manage, by naming, lumping and criteria-zing. This review will discuss these, what we consider ill-advised attempts, with recent examples. Recent findings: It is in vogue to call Sjögren's syndrome, Sjögren's disease. This was boosted by popular vote during a recent medical meeting, an unusual mode of coming to agreements in science. Behçet syndrome is still called Behçet disease by many colleagues despite its still mostly undeciphered disease mechanisms and different phenotypes. There have been recent attempts not only to re-lump Behçet syndrome with seronegative spondarthritides but also with Takayasu arteritis. On the other hand, in some instances, Takayasu arteritis can only be differentiated from giant cell arteritis by the age of the patient. Designing classification criteria for various conditions is still popular while criteria proponents maintain they are strictly for research purposes, ignoring the fact that the hypothesis of a research project is the sole determinant of the related criteria. We also maintain that these criteria can be useful for diagnosis and research only as guidelines. Summary: We propose that uncertainty still much present in the practice of medicine should not lead us to resort to naming, lumping and criteria-zing. We have to be more honest and vocal with our patients, our students and everyone involved in providing care for the sick about this inherent uncertainty.
- 27 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
Uncertainty in medicine and vasculitis
Purpose of review: We propose that clinicians/researchers attempt to address the continuing uncertainty of the root causes of the conditions we try to manage, by naming, lumping and criteria-zing. This review will discuss these, what we consider ill-advised attempts, with recent examples. Recent findings: It is in vogue to call Sjögren's syndrome, Sjögren's disease. This was boosted by popular vote during a recent medical meeting, an unusual mode of coming to agreements in science. Behçet syndrome is still called Behçet disease by many colleagues despite its still mostly undeciphered disease mechanisms and different phenotypes. There have been recent attempts not only to re-lump Behçet syndrome with seronegative spondarthritides but also with Takayasu arteritis. On the other hand, in some instances, Takayasu arteritis can only be differentiated from giant cell arteritis by the age of the patient. Designing classification criteria for various conditions is still popular while criteria proponents maintain they are strictly for research purposes, ignoring the fact that the hypothesis of a research project is the sole determinant of the related criteria. We also maintain that these criteria can be useful for diagnosis and research only as guidelines. Summary: We propose that uncertainty still much present in the practice of medicine should not lead us to resort to naming, lumping and criteria-zing. We have to be more honest and vocal with our patients, our students and everyone involved in providing care for the sick about this inherent uncertainty.
- 7 May 2026
- Published by Wiley in Arthritis & Rheumatology
Potential Confounding by Weight Loss: Comment on the article by Jorge et al.
- 7 May 2026
- Published by Wiley in Arthritis & Rheumatology
Potential Confounding by Weight Loss: Comment on the article by Jorge et al.
- 17 March 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 100, 102758
A critical look at the evolution of randomized controlled trials: new and old ethical issues
- 17 March 2026
- Published by Elsevier in Current Opinion in Immunology
- Vol. 100, 102758
A critical look at the evolution of randomized controlled trials: new and old ethical issues
- 27 June 2025
- Published by Elsevier in Current Opinion in Immunology
- Vol. 95
Can we cure Behçet syndrome?
- 27 June 2025
- Published by Elsevier in Current Opinion in Immunology
- Vol. 95
Can we cure Behçet syndrome?
- Open Access
- 25 January 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-10
Safety outcome trials in four mainline medical journals 30 years apart: a narrative review and the need for the transparency of informed consents
It was our impression that safety outcome trials were getting more frequent, raising ethical issues mainly related to patient autonomy. We and others had also proposed this autonomy would be best served if wording of the informed consents would be in the public domain. Initially two observers and an arbiter tabulated the main aims of randomized controlled trials (RCTs) published in 1990–1991 vs. 2019–2020 as efficacy, safety, or undecided in four mainline medical journals, from the websites. A pragmatic design as well as other salient features was also tabulated. After noting too many trials were categorized as undecided, two additional independent observers and the arbiter did a reassessment. In our reassessment of 889 RCTs, 309 in earlier and 580 in the later time period, 828 (93%) were categorized as efficacy and 47 (5%) as a safety trial. We were undecided in 14 (2%) trials. The proportion of safety outcome trials between the two time periods were similar [14/309 (5%) vs. 33/580 (6%)] while RCTs of any category conducted in the critical care settings notably increased in time [12/309 (4%) vs. 52/580 (9%) OR 2.4; 1.3–4.6]. Death was a primary outcome measure in 0/14 among the earlier and 16/33 (49%) among the later safety outcome trials. Stroke in 9 and myocardial infarction in 8 safety outcome trials were additional primary outcome measures in the same group. There were 2 pragmatic trials in the earlier and 93 in the later period. Although we did not observe a differential increase among the safety outcome trials of all categories, those in critical care settings had significantly increased in time. So did the safety outcome trials with primary outcome measures like death, myocardial infarction, and stroke as well as randomized controlled trials with a pragmatic design. These raise the issue of autonomy related to how clearly the sought-after safety through designing empirical studies primarily to quantitate harm had been worded to the trial participants in plain language. We maintain this issue cannot be adequately addressed unless the informed consent forms, especially for safety outcome trials, are in the public domain.
- 25 January 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-10
Open AccessSafety outcome trials in four mainline medical journals 30 years apart: a narrative review and the need for the transparency of informed consents
It was our impression that safety outcome trials were getting more frequent, raising ethical issues mainly related to patient autonomy. We and others had also proposed this autonomy would be best served if wording of the informed consents would be in the public domain. Initially two observers and an arbiter tabulated the main aims of randomized controlled trials (RCTs) published in 1990–1991 vs. 2019–2020 as efficacy, safety, or undecided in four mainline medical journals, from the websites. A pragmatic design as well as other salient features was also tabulated. After noting too many trials were categorized as undecided, two additional independent observers and the arbiter did a reassessment. In our reassessment of 889 RCTs, 309 in earlier and 580 in the later time period, 828 (93%) were categorized as efficacy and 47 (5%) as a safety trial. We were undecided in 14 (2%) trials. The proportion of safety outcome trials between the two time periods were similar [14/309 (5%) vs. 33/580 (6%)] while RCTs of any category conducted in the critical care settings notably increased in time [12/309 (4%) vs. 52/580 (9%) OR 2.4; 1.3–4.6]. Death was a primary outcome measure in 0/14 among the earlier and 16/33 (49%) among the later safety outcome trials. Stroke in 9 and myocardial infarction in 8 safety outcome trials were additional primary outcome measures in the same group. There were 2 pragmatic trials in the earlier and 93 in the later period. Although we did not observe a differential increase among the safety outcome trials of all categories, those in critical care settings had significantly increased in time. So did the safety outcome trials with primary outcome measures like death, myocardial infarction, and stroke as well as randomized controlled trials with a pragmatic design. These raise the issue of autonomy related to how clearly the sought-after safety through designing empirical studies primarily to quantitate harm had been worded to the trial participants in plain language. We maintain this issue cannot be adequately addressed unless the informed consent forms, especially for safety outcome trials, are in the public domain.
- 28 November 2024
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 37 (1) , 1-2
Introduction, vasculitis 2025
- 28 November 2024
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 37 (1) , 1-2
Introduction, vasculitis 2025
- 30 November 2023
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 36 (1) , 1-2
Introduction, Vasculitis 2023
- 30 November 2023
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 36 (1) , 1-2
Introduction, Vasculitis 2023
- Open Access
- 1 November 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (2) , 114-116
Are Disease Classification Criteria for Diagnosis or for Research? In Fact, for Neither
A popular viewpoint is that disease classification criteria, usually developed for conditions with uncertain disease mechanisms, should not be used in diagnosing patients. They are for research purposes and aim to homogenize study patient characteristics to better interpret research outcomes from diverse research centers.1
- 1 November 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (2) , 114-116
Open AccessAre Disease Classification Criteria for Diagnosis or for Research? In Fact, for Neither
A popular viewpoint is that disease classification criteria, usually developed for conditions with uncertain disease mechanisms, should not be used in diagnosing patients. They are for research purposes and aim to homogenize study patient characteristics to better interpret research outcomes from diverse research centers.1
- 28 July 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (9) , 1683
A probable ecologic bias in the article on the progression of knee osteoarthritis: comment on the article by Lo et al
- 28 July 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (9) , 1683
A probable ecologic bias in the article on the progression of knee osteoarthritis: comment on the article by Lo et al